StemCells, Inc. To Present At Two Investor Conferences In September
PALO ALTO, Calif., September 8, 2009 – StemCells, Inc. (NASDAQ: STEM) announced today that President and Chief Executive Officer Martin McGlynn will present an update on the Company’s programs and operations at the Thomas Weisel Partners Healthcare Conference 2009 on Friday, September 11, and at the ThinkEquity Sixth Annual Growth ConferenceG6 on Wednesday, September 16. Details for each conference are as follows:
Conference: |
ThinkEquity Sixth Annual Growth Conference: G6 |
Location: |
San Francisco, CA |
Date & Time: |
Wednesday, September 16 – 2:15 p.m. Pacific Time, followed by a breakout session. |
Live Webcast & Replay: |
http://www.wsw.com/ or
http://www.stemcellsinc.com under the Investors section |
Interested parties are encouraged to connect to the website at least 15 minutes prior to the live presentation to ensure adequate time for any software downloads that may be necessary to listen to the webcast. A replay will also be accessible for a period of 30 days following the event.
About StemCells, Inc.
StemCells, Inc. is focused on the development and commercialization of cell-based technologies. In its therapeutic product development programs, StemCells is targeting diseases of the central nervous system and liver. StemCells’ lead product candidate, HuCNS-SC ® cells (purified human neural stem cells), is in clinical development for the treatment of two fatal neurodegenerative disorders that primarily affect young children. StemCells also markets specialty cell culture media products under the brand SC Proven ®, and is developing its cell-based technologies for use in drug discovery and development. The Company has exclusive rights to approximately 55 issued or allowed U.S. patents and approximately 200 granted or allowed non-U.S. patents. Further information about StemCells is available on its web site at www.stemcellsinc.com.
Apart from statements of historical fact, the text of this press release constitutes forward-looking statements within the meaning of the U.S. securities laws, and is subject to the safe harbors created therein. These statements include, but are not limited to, statements regarding the clinical development of its HuCNS-SC cells; the prospects for the Company to pursue non-therapeutic applications of its cell-based technologies; and the future business operations of the Company. These forward-looking statements speak only as of the date of this news release. The Company does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. Such statements reflect management’s current views and are based on certain assumptions that may or may not ultimately prove valid. The Company’s actual results may vary materially from those contemplated in such forward-looking statements due to risks and uncertainties to which the Company is subject, including those described under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2008 and in its subsequent reports on Form 10-Q and Form 8-K.
#########################
CONTACT: StemCells, Inc.
Megan Meloni
Investor Relations
650-475-3100, Ext. 105
irpr@stemcellsinc.com
SOURCE: StemCells, Inc.
|
